Avalyn Pharma Inc.

This study tests an inhaled form of pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their usual care. T…

This study tests an inhaled version of the drug nintedanib (AP02) in 160 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Participants will inhale the drug or a placebo twice daily for 12 weeks. The goal is to see if it improves lung function and is safe.…

This study looks at the long-term safety of an inhaled medication for people with progressive lung scarring (pulmonary fibrosis). Participants must have completed a prior Avalyn Pharma study of the same drug. Researchers will monitor side effects and lung function over time to se…